Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Enanta Pharma (ENTA) Misses Q4 EPS by 9c, Revenues Miss
November 21, 2019 4:01 PM ESTEnanta Pharma (NASDAQ: ENTA) reported Q4 EPS of $0.44, $0.09 worse than the analyst estimate of $0.53. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.94 million.
Initiation of RSVP, a Phase 2b study of EDP-938 in adult outpatients with RSVEDP-297 selected as follow-on FXR agonist with differentiated preclinical profileRoyalty revenue for the quarter was $51.3 millionCash and marketable securities totaled approximately $400 million at September 30, 2019During 2019, we successfully... More
